Anti-inflammatory phytochemicals for the treatment of diabetes and its complications: Lessons learned and future promise - 19/12/20
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 15 |
| Iconographies | 5 |
| Vidéos | 0 |
| Autres | 0 |
Graphical abstract |
Highlights |
• | Type 2 diabetes and its complications are predominantly characterized by chronic, low-grade and systemic inflammation. |
• | Inflammatory response is one of key driving forces to promote the pathogenesis of diabetes and its complications. |
• | Bioactive phytochemicals possessing anti-inflammatory benefits hold great promise for the treatment of diabetes. |
• | The review critically appraises the therapeutic promise of anti-inflammatory phytochemicals for diabetes treatment. |
Abstract |
Diabetes mellitus (type 1 and type 2) and its various complications continue to place a huge burden on global medical resources, despite the availability of numerous drugs that successfully lower blood glucose levels. The major challenging issue in diabetes management is the prevention of various complications that remain the leading cause of diabetes-related mortality. Moreover, the limited long-term durability of monotherapy and undesirable side effects of currently used anti-diabetic drugs underlie the urgent need for novel therapeutic approaches. Phytochemicals represent a rich source of plant-derived molecules that are of pivotal importance to the identification of compounds with therapeutic potential. In this review, we aim to discuss recent advances in the identification of a large array of phytochemicals with immense potential in the management of diabetes and its complications. Given that metabolic inflammation has been established as a key pathophysiological event that drives the progression of diabetes, we focus on the protective effects of representative phytochemicals in metabolic inflammation. This paper also discusses the potential of phytochemicals in the development of new drugs that target the inflammation in the management of diabetes and its complications.
Le texte complet de cet article est disponible en PDF.Abbreviations : AMPK, BCAAs, COX-2, CCL5, DM, DKD, DR, DPN, ERK, GDM, HepG2, iNOS, IL, ICAM-1, JNK, MAPKs, MCP-1, NF-κB, NAFLD, NLRP3, NRF2, PTP-1B, PPAR-γ, ROS, STZ, SIRT1, T1DM, T2DM, TNF-α, TGF-β1, TLR4, VCAM-1, VEGF
Keywords : Diabetes mellitus, Anti-inflammation, Phytochemicals, Bioactive compounds
Plan
Vol 133
Article 110975- janvier 2021 Retour au numéro
Article précédent
- Gallic acid: Pharmacological activities and molecular mechanisms involved in inflammation-related diseases
- Jinrong Bai, Yunsen Zhang, Ce Tang, Ya Hou, Xiaopeng Ai, Xiaorui Chen, Yi Zhang, Xiaobo Wang, Xianli Meng
- Inhibiting RRM2 to enhance the anticancer activity of chemotherapy
- Yaqiong Zhan, Lushun Jiang, Xuehang Jin, Shuaibing Ying, Zhe Wu, Li Wang, Wei Yu, Jiepeng Tong, Li Zhang, Yan Lou, Yunqing Qiu
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?